Annexon biosciences to participate in the cowen 42nd annual healthcare conference

Brisbane, calif., feb. 28, 2022 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that douglas love, esq., president and chief executive officer, will participate in a virtual panel titled, “orphan cns panel,” during the cowen 42nd annual healthcare conference on tuesday, march 8, 2022, at 2:10 p.m. et.
ANNX Ratings Summary
ANNX Quant Ranking